Dai Chihara1, Yasuhiro Oki2. 1. Department of Internal Medicine, MSC10 55501, The University of New Mexico, Albuquerque, NM, 87131, USA. dchihara-kob@umin.ac.jp. 2. Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
PURPOSE OF REVIEW: Central nervous system (CNS) involvement in peripheral T cell lymphoma (PTCL) is a difficult condition to treat, both as a primary and a secondary disease. RECENT FINDINGS: Primary CNS lymphoma (PCNSL) in PTCL is very rare, making up only 2% of all PCNSLs. The incidence of CNS relapse is generally 2-6% in all cases of PTCL, but the risk may vary by histologic subtype, and extranodal involvement > 1 has been consistently found to be a risk factor for CNS relapse. Currently, there is no consensus about indications for CNS prophylactic treatment. A high-dose systemic methotrexate-based regimen is the most commonly used treatment, with or without consolidation with high-dose chemotherapy with autologous stem cell transplantation for both primary and secondary CNS involvement. This approach, however, is generally toxic for older patients. New therapeutic approaches against PTCL are therefore needed.
PURPOSE OF REVIEW: Central nervous system (CNS) involvement in peripheral T cell lymphoma (PTCL) is a difficult condition to treat, both as a primary and a secondary disease. RECENT FINDINGS:Primary CNS lymphoma (PCNSL) in PTCL is very rare, making up only 2% of all PCNSLs. The incidence of CNS relapse is generally 2-6% in all cases of PTCL, but the risk may vary by histologic subtype, and extranodal involvement > 1 has been consistently found to be a risk factor for CNS relapse. Currently, there is no consensus about indications for CNS prophylactic treatment. A high-dose systemic methotrexate-based regimen is the most commonly used treatment, with or without consolidation with high-dose chemotherapy with autologous stem cell transplantation for both primary and secondary CNS involvement. This approach, however, is generally toxic for older patients. New therapeutic approaches against PTCL are therefore needed.
Entities:
Keywords:
Central nervous system; Peripheral T cell lymphoma; Relapse; Review
Authors: Anita Kumar; Ann Vanderplas; Ann S LaCasce; Maria A Rodriguez; Allison L Crosby; Eva Lepisto; Myron S Czuczman; Auayporn Nademanee; Joyce Niland; Leo I Gordon; Michael Millenson; Andrew D Zelenetz; Jonathan W Friedberg; Gregory A Abel Journal: Cancer Date: 2011-10-17 Impact factor: 6.860
Authors: Antonio Omuro; Denise D Correa; Lisa M DeAngelis; Craig H Moskowitz; Matthew J Matasar; Thomas J Kaley; Igor T Gavrilovic; Craig Nolan; Elena Pentsova; Christian C Grommes; Katherine S Panageas; Raymond E Baser; Geraldine Faivre; Lauren E Abrey; Craig S Sauter Journal: Blood Date: 2015-01-07 Impact factor: 22.113
Authors: Igor T Gavrilovic; Adília Hormigo; Joachim Yahalom; Lisa M DeAngelis; Lauren E Abrey Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: H-T Arkenau; G Chong; D Cunningham; D Watkins; R Agarwal; B Sirohi; M Trumper; A Norman; A Wotherspoon; A Horwich Journal: Ann Oncol Date: 2006-12-12 Impact factor: 32.976
Authors: T Hayakawa; K Takakura; H Abe; T Yoshimoto; R Tanaka; K Sugita; H Kikuchi; T Uozumi; T Hori; H Fukui Journal: J Neurooncol Date: 1994 Impact factor: 4.130
Authors: Hany R Guirguis; Matthew C Cheung; Mervat Mahrous; Eugenia Piliotis; Neil Berinstein; Kevin R Imrie; Liying Zhang; Rena Buckstein Journal: Br J Haematol Date: 2012-07-31 Impact factor: 6.998
Authors: Vivien Mak; Jeremey Hamm; Mukesh Chhanabhai; Tamara Shenkier; Richard Klasa; Laurie H Sehn; Diego Villa; Randy D Gascoyne; Joseph M Connors; Kerry J Savage Journal: J Clin Oncol Date: 2013-04-22 Impact factor: 44.544
Authors: C Schultz; C Scott; W Sherman; B Donahue; J Fields; K Murray; B Fisher; R Abrams; J Meis-Kindblom Journal: J Clin Oncol Date: 1996-02 Impact factor: 44.544